|
Patent landscape, scope, and claims: |
United States Patent 12,070,459: Scope of Claims for Lumateperone Mono-Tosylate Solid-Crystal Hard Capsules and the US Patent Landscape
US Patent No. 12,070,459 claims an oral hard-shelled capsule formulation of lumateperone in the mono-tosylate salt form using a specific solid-crystal physical form (crystal identity by XRPD peak set and particle-size/PSD limits) and a specific capsule composition and performance envelope (lumateperone PK under fasting: Cmax/Tmax/AUC(0-inf) ranges), plus dependent claims adding colorants, specific excipient blend ranges, dissolution thresholds, and a 5-HT2A/SERT/D1/D2 pathway treatment method with an extended disease/disorder list.
The practical IP boundary is narrow on composition-structure (salt form + crystalline identity + PSD) and functional performance (fasted PK bands and dissolution), which generally favors formulation-generic non-infringement defenses that redesign crystal form, particle size/PSD, excipient ratios, or PK profile.
What is the exact claim scope of US Patent 12,070,459 for lumateperone mono-tosylate capsules?
Core independent claim (Claim 1) covers:
- An oral pharmaceutical capsule containing lumateperone mono-tosylate where:
- The lumateperone mono-tosylate is in solid crystal form.
- The capsule contains about 60 mg lumateperone mono-tosylate in solid crystal form.
- The capsule contains a blend of 10 to 30% by weight of lumateperone mono-tosylate (solid crystals) plus pharmaceutically acceptable carriers including at least one of:
- diluent/filler, binder, disintegrant, lubricant, glidant
- A fasting single-capsule oral dose performance constraint:
- Cmax of lumateperone: 15–55 ng/mL and/or
- Tmax: 0.7–1.5 hours and/or
- AUC(0-inf): 51–135 hr·ng/mL
Claim 1 is drafted as a formulation plus PK performance window. In US practice, this creates a dual infringement hook:
- Product identity: salt form + solid crystal form + composition blend.
- Functional envelope: if the accused product’s fasted PK lies within the recited ranges (or the claim is interpreted as requiring “and/or” conditions in a way that preserves coverage).
How does Claim 1 treat “and/or” PK limitations?
Claim 1 recites “provides a maximal plasma concentration … and/or” Tmax and/or AUC(0-inf). The claim language can be argued as permitting coverage when any one of the PK parameters falls in range. For litigation exposure mapping, this broadens functional risk compared with claims requiring all three parameters simultaneously.
Which dependent claims narrow composition, crystal form, and excipient ratios?
What formulations are protected by Claims 2–10 (colorants, excipient specifics, capsule type, coatings)?
- Claim 2 adds optional colorants:
- FD&C Yellow #6, FD&C Blue #1, FD&C Red #3, black iron oxide, red iron oxide, titanium dioxide, or combinations.
- Claim 3 locks a specific blend (typical infringement discriminator for formulation generics):
- 10–30% by weight lumateperone mono-tosylate solid crystals
- 60–90% mannitol
- 0.5–10% croscarmellose sodium
- 0.1–1% talc
- 0.1–3% magnesium stearate
- filled into a gelatin capsule
- Claims 5 and 6–7 provide tighter “consisting of” and “about” embodiments with fixed ranges and optional colorants:
- Claim 5: 70–80% mannitol; 0.5–5% croscarmellose; 0.1–1% talc; 0.1–1% Mg stearate; gelatin capsule.
- Claim 6: about 74% mannitol, 5% croscarmellose, 0.3% talc, 1% Mg stearate + colorants.
- Claim 7: about 87% mannitol, 5% croscarmellose, 0.3% talc, 1.25% Mg stearate + colorants.
- Claim 4 protects the crystal form by XRPD:
- at least two peaks at 2-theta values selected from a listed set (examples below), each ±0.2°, measured with Cu anode + nickel filter.
- Listed 2-theta values: 5.68°, 12.11°, 16.04°, 17.03°, 18.16°, 19.00°, 21.67°, 22.55°, 23.48°, 24.30°.
- Claim 8 covers particular carrier systems:
- blend includes lumateperone mono-tosylate solid crystals plus either:
- mannitol, croscarmellose sodium, talc, glyceryl monostearate, and gelatin; or
- mannitol, croscarmellose sodium, talc, magnesium stearate, and gelatin.
- Claim 9: one or more surface coatings.
- Claim 10: capsule is a hard-shelled capsule.
Implication: the claims cluster into (i) crystal identity (XRPD), (ii) PSD particle-size limits (later claims), and (iii) excipient ratio regimes that influence disintegration and absorption. A generic can reduce literal risk by switching to a different crystalline form or shifting excipient ratios outside dependent claim boundaries, but Claim 1 still captures a broad “diluents/carriers” concept and broad PK acceptance window.
How does the patent define the lumateperone crystal and particle-size distribution?
What crystal definition is claimed by XRPD (Claim 4)?
Claim 4 requires the solid crystal form to have an X-ray powder diffraction pattern with:
- at least two peaks among the specified set of 2-theta values:
- 5.68, 12.11, 16.04, 17.03, 18.16, 19.00, 21.67, 22.55, 23.48, 24.30 (each ±0.2)
- with measurement on a diffractometer using Cu anode with a nickel filter.
This is a strong identity limitation: the claim is not merely “crystalline,” it is crystal-defined via XRPD fingerprints.
What particle-size limits are claimed (Claims 11–14)?
- Claim 11: mean particle size 1–200 μm; and/or D90 ≤ 100 μm; and/or D10 ≤ 50 μm.
- Claim 13 tightens:
- mean particle size 1–5 μm; and/or D90 ≤ 10 μm; and/or D10 ≤ 5 μm.
- Claim 14 adds PSD specificity:
- D90 ≤ 10 μm, D10 ≤ 5 μm, and/or PSD D50 of 2–5 μm.
Infringement design-around lever: selecting an alternative crystallization process producing different XRPD peaks or broader PSD can move an accused product outside these dependent limitations, though Claim 1 still covers “solid crystal form” broadly unless the XRPD requirement is imported through construction of “solid crystal form” scope.
What dissolution and fasted pharmacokinetic performance windows are claimed?
Dissolution thresholds (Claim 15)
- Capsule dissolves in 500 mL of 0.1N aqueous HCl:
- at least 85% after 15 min
- at least 92% after 30 min
- at least 94% after 45 min
This is a functional formulation limitation typically sensitive to particle size, disintegrants, and excipient ratios.
Fasted plasma concentration targets (Claims 1, 16–17, 21–28)
Claim 1 provides broad PK coverage. Dependent claims narrow to specific bands:
- Claim 16: mean fasted PK:
- Cmax 30–40 ng/mL and/or
- Tmax 1–1.2 h
- AUC(0-inf) 70–115 hr·ng/mL
- Claim 17 tightens further:
- Cmax 30–40 ng/mL
- Tmax about 1 hour
- AUC 85–100 hr·ng/mL
- Claim 21: Cmax 15–55 ng/mL
- Claim 22: Tmax 0.7–1.5 h
- Claim 23: AUC(0-inf) 51–135 hr·ng/mL
- Claims 24–28 restate the Claim 16/17 bands in separate dependent formatting:
- Cmax 30–40 ng/mL
- Tmax 1–1.2 h
- AUC 70–115 hr·ng/mL
- Tmax about 1 h
- AUC 85–100 hr·ng/mL
What does the PK scope mean for infringement risk?
- If an accused lumateperone capsule is developed to match the marketed product’s fasted exposure, it is likely to fall inside these windows.
- If an accused product is designed for food-effect or uses a different crystalline/particle-size/excipient strategy to alter absorption kinetics, it may shift Cmax/Tmax/AUC out of range and avoid literal coverage even if XRPD overlaps.
What method-of-treatment claims are asserted and how broad is the disease list?
What is claimed by Claim 12 and expanded by Claims 18–19?
- Claim 12: method of treating a disease/disorder mediated by signaling pathways involving:
- 5-HT2A receptor
- SERT (serotonin transporter)
- dopamine D1/D2 receptor signaling pathways
by administering the capsule of Claim 1.
- Claim 18: selected diseases/disorders include:
- obesity, anorexia, bulimia
- depression and acute depression, post-traumatic depression
- anxiety and acute anxiety, panic disorders, phobias, social anxiety disorder
- social withdrawal, psychosis, acute psychosis
- schizophrenia; positive and/or negative symptoms of schizophrenia
- obsessive-compulsive disorder
- migraine
- ADHD and ADHD hyperactivity disorder
- sleep disorders
- anger disorders, agitation
- dementia, Alzheimer’s disease
- Parkinson’s dementia
- bipolar disorder, bipolar depression
- behavioral disturbances associated with autism
- Claim 19 narrows to:
- depression, major depressive disorder
- schizophrenia, negative symptoms of schizophrenia
- bipolar disorder, bipolar depression
IP boundary: the medical method claim attaches to administration of the claimed capsule. If the capsule is not covered, the method claim generally does not extend coverage by itself; it is a secondary infringement vector.
What metabolite and exposure ratio claims are included (Claim 20)?
Claim 20 adds a metabolite exposure profile when administering about 60 mg lumateperone mono-tosylate:
- Metabolites A, B, C, E, F defined “as follows” (definitions omitted in the excerpt you provided).
- It asserts multiple ranges for mean Cmax and AUC(0-inf) for each metabolite, plus ratios of metabolite exposure vs parent lumateperone exposure, such as:
- ratio Cmax (metabolite A)/Cmax (lumateperone) 0.8–1.3
- ratio Cmax (metabolite B)/Cmax (lumateperone) 0.5–0.8
- ratio Cmax (metabolite C)/Cmax (lumateperone) 0.5–0.8
- ratio Cmax (metabolite E)/Cmax (lumateperone) 0.3–0.4
- ratio Cmax (metabolite F)/Cmax (lumateperone) 0.5–0.8
- ratios for AUC(0-inf) and corresponding metabolite bands (e.g., metabolite A/AUC parent 3.2–4.8, metabolite F 3.9–6.0, etc.)
Practical effect: this metabolite-ratio burden increases the evidentiary difficulty for a challenger attempting to avoid coverage solely by shifting parent PK. But in patent litigation, metabolite endpoints are typically used only if the accused product is otherwise within the claim’s structural limitations, and if discovery/testing establishes the metabolite ratios also overlap.
How to map the patent landscape around this formulation claim (US) using the claims themselves?
Based on the claim text alone (independent of Orange Book, prosecution history, or cited prior art), the landscape dimensions created by this patent are:
1) Crystal form family risk: XRPD-identified solid crystal
- Likely to be a later “solid form”/“polymorph” style claim set, since it locks to peak positions and measurement conditions.
- Any US ANDA that selects a different crystalline form, or amorphous material, or alternative salt hydrate/solvate, can pursue non-infringement.
2) Particle engineering risk: PSD, D10/D90, mean particle size
- Dependent claims (11–14) create a narrow infringement window tied to manufacturing particle size control.
- Risk increases if a candidate ANDA uses jet milling or recrystallization steps that yield the same PSD envelope.
3) Excipient ratio and dissolution engineering risk
- Claims (3, 5, 6, 7, 8) create a “formulation infringement map” based on excipient percentages and disintegration/lubrication profiles.
- Dissolution in 0.1N HCl at specific time points is an additional functional limiter (Claim 15).
4) PK window risk in fasting conditions
- If the ANDA targets bioequivalence that implicitly reproduces lumateperone’s exposure profile, it may land inside the claimed Cmax/Tmax/AUC windows.
- Because Claim 1 uses “and/or,” the functional boundary can be interpreted broadly.
5) Metabolite ratio risk (Claim 20)
- Adds a layer that can capture products that otherwise match parent exposure while differing in metabolite distributions only within claimed ratios.
Where could generic entry or biosimilar-style design-arounds be most effective?
This patent is formulation-specific to an oral capsule of lumateperone mono-tosylate. For a generic candidate, the highest-leverage design-arounds implied by the claim architecture are:
- Change crystal form so the XRPD peak set (Claim 4) is not met for the required ±0.2° peaks.
- Shift particle size/PSD so Claim 11/13/14 dependent limits are not met, and argue “solid crystal form” in Claim 1 does not cover the alternative PSD if the claim construction ties “solid crystal form” to those dependent limitations.
- Adjust excipient ratios so the formulation falls outside Claim 3/5/6/7/8 ranges, particularly mannitol and croscarmellose sodium levels.
- Alter dissolution kinetics so Claim 15 fails at one or more time points in 0.1N HCl (at least 85% at 15 min, 92% at 30 min, 94% at 45 min).
- Shift fasted PK outside the bands and use “PK out-of-range” as a non-infringement narrative.
- Avoid metabolite ratio overlap by shifting absorption or metabolism endpoints so Claim 20 ratios fall outside.
Key Takeaways
- US 12,070,459 is an oral hard-capsule formulation patent centered on lumateperone mono-tosylate solid crystals with XRPD fingerprint limits, PSD controls, specific excipient regimes, and fasted PK (Cmax/Tmax/AUC0-inf) performance windows.
- Claim 1 is broad on PK because it uses “and/or”, increasing exposure if an accused product overlaps on any single PK parameter within the ranges.
- Dependent claims add tight discriminators: specific mannitol/croscarmellose/talc/Mg stearate blends, optional FD&C/color mineral additives, 0.1N HCl dissolution benchmarks, and an expanded disease treatment list tied to 5-HT2A/SERT/D1-D2 signaling pathways.
- The claim set provides multiple orthogonal non-infringement routes for generics: crystal form (XRPD), particle size distribution, excipient ratios, dissolution, and fasted PK (plus metabolite ratios).
FAQs
-
Can a generic avoid infringement by using a different lumateperone salt form or amorphous material?
If the accused drug is not “lumateperone mono-tosylate in solid crystal form” with XRPD peak characteristics, literal infringement risk on the crystalline identity should drop.
-
Which claim element most directly constrains manufacturing risk in US 12,070,459?
The combination of XRPD-defined crystal peaks (Claim 4) and PSD/particle-size limits (Claims 11–14) directly constrains solid-state processing.
-
Does Claim 15 require all dissolution time points to be met?
Claim 15 uses “and/or” language in your excerpt; infringement arguments will turn on claim construction. If treated as requiring the stated thresholds, failing any one time point can be a defensive target.
-
Are metabolite ratios necessary for infringement?
Metabolite ratios appear in dependent Claim 20; they only become relevant if Claim 20 is asserted as part of the infringement theory alongside its parent limitations.
-
How does the disease list in Claim 18 affect generic drug development risk?
It broadens method-of-use coverage, but method claims typically depend on using the claimed capsule for the treating act.
References
- US Patent No. 12,070,459 (claim set provided in prompt).
More… ↓
⤷ Start Trial
|
